Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Asset Writedowns and Impairment: 2010-2025

Historic Asset Writedowns and Impairment for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $1.1 million.

  • Anika Therapeutics' Asset Writedowns and Impairment fell 63.66% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year decrease of 63.93%. This contributed to the annual value of $44.7 million for FY2024, which is 28.11% down from last year.
  • Per Anika Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $1.1 million for Q3 2025, which was down 62.56% from $3.0 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Asset Writedowns and Impairment high stood at $59.6 million for Q4 2023, and its period low was $89,000 during Q2 2022.
  • Over the past 3 years, Anika Therapeutics' median Asset Writedowns and Impairment value was $1.6 million (recorded in 2024), while the average stood at $9.0 million.
  • Per our database at Business Quant, Anika Therapeutics' Asset Writedowns and Impairment slumped by 83.53% in 2021 and then soared by 3,559.89% in 2023.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Asset Writedowns and Impairment stood at $2.9 million in 2021, then plummeted by 44.36% to $1.6 million in 2022, then soared by 3,559.89% to $59.6 million in 2023, then tumbled by 68.73% to $18.6 million in 2024, then slumped by 63.66% to $1.1 million in 2025.
  • Its Asset Writedowns and Impairment stands at $1.1 million for Q3 2025, versus $3.0 million for Q2 2025 and $832,000 for Q1 2025.